8-K
filed May 21, 2026, 5:06 PM ET
ticker QNCX
CIK 0001662774
regulatory
confidence high
sentiment positive
materiality 0.20
Quince Therapeutics regains Nasdaq listing compliance via equity alternative
Quince Therapeutics, Inc.
- Company had been notified of MVLS deficiency on March 17, 2026.
- On May 20, 2026, Staff confirmed compliance based on Q1 2026 stockholders' equity of $15.672M under Rule 5450(b)(1)(A).
- Matter is now closed; no further action required.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-234858
- form_type
- 8-K
- ticker
- QNCX
- cik
- 0001662774
- company_name
- Quince Therapeutics, Inc.
- filed_at
- 2026-05-21T21:06:52+00:00
- discovered_at
- 2026-05-21T21:08:00.264922+00:00
- generated_at
- 2026-05-21T21:10:24.753204+00:00
- sec_items
- ["8.01"]
- event_type
- regulatory
- sentiment
- positive
- materiality_score
- 0.2
- calibrated_materiality_score
- 0.2
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-234858
- json_url
- https://secwatch.observer/filing/0001193125-26-234858.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-234858.md
- text_url
- https://secwatch.observer/filing/0001193125-26-234858.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1662774/000119312526234858/0001193125-26-234858-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1662774/000119312526234858/d139014d8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
CLIR
ClearSign Technologies suspends ATM prospectus supplement for $10.39 million common stock offering; no shares sold
ClearSign Technologies Corp
May 28, 2026, 4:19 PM ET
regulatory
Items 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
AIRE
reAlpha regains Nasdaq minimum bid price compliance; matter closed
reAlpha Tech Corp.
May 14, 2026, 4:20 PM ET
regulatory
Items 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
MSS
Maison Solutions regains Nasdaq minimum bid price compliance; listing continues
Maison Solutions Inc.
May 12, 2026, 1:22 PM ET
regulatory
Items 7.01, 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
RICK
RCI Hospitality regains Nasdaq compliance after filing delayed Q1 10-Q
RCI HOSPITALITY HOLDINGS, INC.
June 1, 2026, 3:08 PM ET
regulatory
Items 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
Filing page
SEC filing
OTLK
Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days
Outlook Therapeutics, Inc.
June 1, 2026, 9:15 AM ET
regulatory
Items 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
Filing page
SEC filing
VYGR
FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's
Voyager Therapeutics, Inc.
June 1, 2026, 8:00 AM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
Filing page
SEC filing
EXFY
Expensify regains Nasdaq minimum bid price compliance
Expensify, Inc.
May 29, 2026, 5:15 PM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
Filing page
SEC filing
SLXN
Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted
Silexion Therapeutics Corp
May 29, 2026, 7:00 AM ET
regulatory
Items 3.03, 5.03, 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.